Interleukin-6 as an Early Chronic Inflammatory Marker in Polycystic Ovary Syndrome with Insulin Receptor Substrate-2 Polymorphism

Authors


Meng-Hsing Wu, Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 138 Sheng-Li Road, 70428 Tainan, Taiwan.
E-mail: mhwu68@mail.ncku.edu.tw

Abstract

Citation Lin Y-S, Tsai S-J, Lin M-W, Yang C-T, Huang M-F, Wu M-H. Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism. Am J Reprod Immunol 2011; 66: 527–533

Problem  Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disorder. This study was to evaluate whether insulin receptor substrate (IRS)-2 Gly1057Asp polymorphism influences chronic inflammatory parameters in Taiwanese patients with PCOS.

Method of study  DNA was extracted from whole blood samples for genotyping and detection of IRS-2 Gly1057Asp polymorphism in 129 PCOS women and 109 control women. Ninety-seven PCOS women accepted metformin treatment for 3 months, and low-grade chronic inflammatory markers were assessed.

Results  The levels of IL-6 were significantly elevated in PCOS women compared with normal women. Among allelic variant of IRS-2, concentrations of IL-6 were greater in IRS-2 homozygous Asp population. Treatment with metformin significantly reduced IL-6, especially in PCOS patients with IRS-2 homozygous Asp variant.

Conclusion  The results showed that IL-6 may be an early low-grade chronic inflammatory marker among PCOS patients with IRS-2 polymorphism in Taiwanese population. This pharmacologic study in IRS-2 polymorphism may provide more information for preventing long-term complications in PCOS.

Ancillary